How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from a retrospective cohort study in Zambia

Lise Jamieson(National Research Foundation), Brooke E Nichols(Boston University), Anna Grimsrud(International AIDS Society), Mpande Mukumbwa-Mwenechanya(Boston University), Bevis Phiri(Clinton Health Access Initiative), Sydney Rosen(Boston University), Hilda Shakwelele, Priscilla Lumano‐Mulenga(Ministry of Health), Prudence Haimbe, Muya Mwansa(Ministry of Health), Innocent Chiboma(Ministry of Health)
BMJ Open
December 1, 2022
10.1136/bmjopen-2022-064070
Cited by 17

Related Papers

Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial
|PLoS Medicine|2016|331
Retention in care and viral suppression in differentiated service delivery models for HIV treatment delivery in sub‐Saharan Africa: a rapid systematic review
|Journal of the International AIDS Society|2020|161
Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa
|PLoS Medicine|2019|151
Evidence for scale up: the differentiated care research agenda
|Journal of the International AIDS Society|2017|147
Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis
|Global Health Science and Practice|2021|76